BRPI0108386B8 - conjugado de uricase, composição farmacêutica e método para a purificação de uricase - Google Patents

conjugado de uricase, composição farmacêutica e método para a purificação de uricase

Info

Publication number
BRPI0108386B8
BRPI0108386B8 BRPI0108386A BR0108386A BRPI0108386B8 BR PI0108386 B8 BRPI0108386 B8 BR PI0108386B8 BR PI0108386 A BRPI0108386 A BR PI0108386A BR 0108386 A BR0108386 A BR 0108386A BR PI0108386 B8 BRPI0108386 B8 BR PI0108386B8
Authority
BR
Brazil
Prior art keywords
uricase
conjugate
purification
pharmaceutical composition
protein
Prior art date
Application number
BRPI0108386A
Other languages
English (en)
Portuguese (pt)
Other versions
BR0108386C1 (pt
BR0108386B1 (pt
BR0108386A (pt
Inventor
David Williams L
S Hershfield Michael
G P Saifer Mark
R Sherman Merry
J Kelly Susan
Original Assignee
Univ Duke
Mountain View Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Mountain View Pharmaceuticals Inc filed Critical Univ Duke
Publication of BR0108386A publication Critical patent/BR0108386A/pt
Publication of BR0108386C1 publication Critical patent/BR0108386C1/pt
Publication of BR0108386B1 publication Critical patent/BR0108386B1/pt
Publication of BRPI0108386B8 publication Critical patent/BRPI0108386B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0108386A 2000-02-10 2001-02-07 conjugado de uricase, composição farmacêutica e método para a purificação de uricase BRPI0108386B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/501,730 US6783965B1 (en) 2000-02-10 2000-02-10 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PCT/US2001/040069 WO2001059078A2 (en) 2000-02-10 2001-02-07 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Publications (4)

Publication Number Publication Date
BR0108386A BR0108386A (pt) 2002-10-29
BR0108386C1 BR0108386C1 (pt) 2011-12-20
BR0108386B1 BR0108386B1 (pt) 2017-10-31
BRPI0108386B8 true BRPI0108386B8 (pt) 2021-05-25

Family

ID=23994789

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0108386A BRPI0108386B8 (pt) 2000-02-10 2001-02-07 conjugado de uricase, composição farmacêutica e método para a purificação de uricase

Country Status (27)

Country Link
US (3) US6783965B1 (enFirst)
EP (3) EP2305819B1 (enFirst)
JP (2) JP5165826B2 (enFirst)
KR (3) KR100884724B1 (enFirst)
CN (2) CN101735991B (enFirst)
AT (1) ATE463576T1 (enFirst)
AU (3) AU2001249975B2 (enFirst)
BE (1) BE2013C045I2 (enFirst)
BR (1) BRPI0108386B8 (enFirst)
CA (1) CA2398679C (enFirst)
CY (3) CY1110142T1 (enFirst)
CZ (1) CZ304864B6 (enFirst)
DE (1) DE60141742D1 (enFirst)
DK (3) DK2305819T3 (enFirst)
ES (2) ES2524153T3 (enFirst)
FR (1) FR13C0036I2 (enFirst)
HU (1) HU227127B1 (enFirst)
IL (3) IL151065A0 (enFirst)
LU (1) LU92237I2 (enFirst)
MX (1) MXPA02007545A (enFirst)
NZ (1) NZ520434A (enFirst)
PL (1) PL208064B1 (enFirst)
PT (2) PT2305819E (enFirst)
RU (3) RU2281954C2 (enFirst)
TW (2) TW200914617A (enFirst)
WO (1) WO2001059078A2 (enFirst)
ZA (1) ZA200207206B (enFirst)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
EP2277998B1 (en) 1998-08-06 2016-04-20 Duke University Urate oxidase
HU226294B1 (en) * 1998-08-06 2008-08-28 Mountain View Pharmaceuticals Peg-urate oxidase conjugates and use thereof
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CA2338665C (en) 1998-08-06 2011-01-18 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
DE60229958D1 (de) 2001-06-28 2009-01-02 Mountain View Pharmaceuticals Polymerstabilisierte proteinasen
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
CA2488558C (en) 2002-06-07 2013-08-20 Dyax Corp. Prevention and reduction of blood loss
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
RS20050502A (sr) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati interferona- beta sa povećanom biološkom aktivnošću
MXPA05012314A (es) 2003-05-12 2006-04-18 Affymax Inc Radical separador para peptido modificado con polietilenglicol.
DK1625156T3 (da) * 2003-05-12 2013-01-07 Affymax Inc Peptider, der bindes til erythropoietinreceptoren
CA2525464A1 (en) * 2003-05-12 2004-11-25 Qun Yin Novel poly(ethylene glycol) modified compounds and uses thereof
DK1663281T3 (en) * 2003-08-29 2014-03-17 Dyax Corp POLY-PEGYLED PROTEASE INHIBITORS
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP2008519858A (ja) * 2004-11-11 2008-06-12 アフィーマックス・インコーポレイテッド エリスロポエチンレセプターに結合する新規ペプチド
WO2006105993A2 (en) * 2005-04-05 2006-10-12 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for shielding functional sites or epitopes on proteins
TWI418564B (zh) * 2005-04-11 2013-12-11 Savient Pharmaceuticals Inc 利用陽離子界面活性劑之蛋白質純化
WO2008051178A2 (en) * 2006-04-12 2008-05-02 Savient Pharmaceuticals, Inc. Purification of proteins with cationic surfactant
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US8188224B2 (en) 2005-04-11 2012-05-29 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
US7811800B2 (en) 2005-04-11 2010-10-12 Savient Pharmaceuticals, Inc. Variant form of urate oxidase and use thereof
JP2008545665A (ja) * 2005-05-23 2008-12-18 ユニベルシテ ドゥ ジュネーブ 高体温による処置のための注入可能な超常磁性ナノ粒子および高体温インプラントを形成するための使用
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP2195010A4 (en) * 2007-08-21 2012-03-14 Genzyme Corp TREATMENT WITH INHIBITORS OF KALLIKREINE
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
EP4635567A3 (en) 2009-06-25 2025-12-03 Horizon Therapeutics USA, Inc. Methods and kits for preventing infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
RS62853B1 (sr) 2010-01-06 2022-02-28 Takeda Pharmaceuticals Co Proteini koji vezuju kalikrein plazme
US8940861B2 (en) 2010-04-08 2015-01-27 Georgia Tech Research Corporation Variants of ancestral uricases and uses thereof
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
EP3003358B1 (en) 2013-06-07 2021-03-24 Allena Pharmaceuticals Inc. Compositions and devices for dialysis
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2917671A1 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
PH12021551647A1 (en) 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
AU2015235967B2 (en) 2014-03-27 2020-10-22 Takeda Pharmaceutical Company Limited Compositions and methods for treatment of diabetic macular edema
AU2016265677B2 (en) 2015-05-15 2021-12-09 Medimmune, Llc Improved uricase sequences and methods of treatment
ES2897959T3 (es) 2015-10-15 2022-03-03 Servier Lab Terapia de combinación para tratar neoplasias malignas
KR20250126877A (ko) 2015-10-15 2025-08-25 르 라보레또레 쎄르비에르 악성 종양의 치료를 위한 조합물 요법
CN116077648A (zh) 2015-12-11 2023-05-09 武田药品工业株式会社 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
CN110234340A (zh) 2016-11-11 2019-09-13 好利恩风湿病制药有限责任公司 泼尼松和尿酸酶分子的组合疗法及其用途
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2019010369A1 (en) 2017-07-07 2019-01-10 Allena Pharmaceuticals, Inc. RECOMBINANT ENZYME URICASE
US20190309269A1 (en) 2018-03-20 2019-10-10 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating hyperuricemia and gout
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN109055260B (zh) * 2018-08-08 2021-11-09 淮海工学院 弯曲芽孢杆菌alkaAU及产尿酸氧化酶方法、产品与应用
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
KR20250041198A (ko) * 2019-05-10 2025-03-25 피이지-바이오 바이오팜 컴퍼니 리미티드 (총칭) 폴리에틸렌 글리콜로 변형된 요산 산화효소
MX2022008649A (es) 2020-01-13 2022-09-23 Takeda Pharmaceuticals Co Inhibidores de calicreina plasmatica y sus usos para tratar episodios de angioedema hereditario pediatrico.
CA3189100A1 (en) 2020-08-10 2022-02-17 Paul PELOSO Methods of treating gout
CN114181917B (zh) * 2022-02-14 2022-06-03 潍坊华卓生物科技有限公司 一种改造尿酸酶、基因序列、制备方法及应用
CN117051026A (zh) * 2022-05-06 2023-11-14 江苏恰瑞生物科技有限公司 一种特异性尿酸结合物固定化树脂及其制备方法和应用
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (enFirst)
FR6301M (enFirst) * 1967-03-29 1968-09-09
US3616231A (en) 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
JPS55135590A (en) 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
CH657141A5 (de) 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
JPS57192435A (en) 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
DE3126759A1 (de) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4847079A (en) 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
DD279486A1 (de) 1986-03-10 1990-06-06 Akad Wissenschaften Ddr Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
JPS6255079A (ja) * 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
JPH085506B2 (ja) * 1986-08-25 1996-01-24 日東製器株式会社 缶容器
DD279489A1 (de) 1986-12-11 1990-06-06 Leuna Werke Veb Verfahren zur herstellung optisch transparenter epoxidharzformmassen
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5955336A (en) * 1988-08-17 1999-09-21 Toyo Boseki Kabushiki Kaisha DNA sequence for uricase and manufacturing process of uricase
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US5382518A (en) 1989-07-13 1995-01-17 Sanofi Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
JPH03148298A (ja) 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd 修飾ペプチドおよびその製造方法
SU1730145A1 (ru) * 1990-05-04 1992-04-30 Всесоюзный научно-исследовательский институт текстильно-галантерейной промышленности Способ стабилизации уриказы
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
DE69233069T2 (de) * 1991-03-15 2003-11-27 Amgen Inc., Thousand Oaks Pegylation von polypeptiden
DE69230613T2 (de) 1991-07-02 2000-12-28 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
AU6240494A (en) 1993-02-16 1994-09-14 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
WO1994023740A1 (en) * 1993-04-22 1994-10-27 Celtrix Pharmaceuticals, Inc. Conjugates of growth factor and bone resorption inhibitor
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
FI972443A7 (fi) 1994-12-07 1997-06-09 Novozymes As Polypeptidi, jonka allergeenisuus on vähentynyt
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
FR2733914B1 (fr) * 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US5853974A (en) 1995-06-07 1998-12-29 Chiron Corporation Enhancement of alkaline phosphatase with SDS in chemiluminescent substrates
JPH09154581A (ja) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
CA2277757C (en) 1997-01-15 2008-09-16 Phoenix Pharmacologics, Inc. Modified tumor necrosis factor
ES2228052T3 (es) * 1998-06-01 2005-04-01 Genentech, Inc. Separacion demonomeros de anticuerpos de sus multimeros utilizando cromatografia de intercambio de iones.
CA2338665C (en) * 1998-08-06 2011-01-18 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
HU226294B1 (en) 1998-08-06 2008-08-28 Mountain View Pharmaceuticals Peg-urate oxidase conjugates and use thereof
EP2277998B1 (en) 1998-08-06 2016-04-20 Duke University Urate oxidase
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US6425448B1 (en) 2001-01-30 2002-07-30 Cdx Gas, L.L.P. Method and system for accessing subterranean zones from a limited surface area
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US9917514B2 (en) 2013-05-24 2018-03-13 Idt Europe Gmbh Non PWM digital DC-DC converter

Also Published As

Publication number Publication date
NZ520434A (en) 2004-05-28
HK1155203A1 (en) 2012-05-11
ES2343105T3 (es) 2010-07-23
HK1143989A1 (en) 2011-01-21
FR13C0036I2 (fr) 2014-05-16
DK1254237T3 (da) 2010-07-19
ES2343105T8 (es) 2013-07-15
ZA200207206B (en) 2003-05-06
EP1254237B1 (en) 2010-04-07
PL208064B1 (pl) 2011-03-31
WO2001059078A2 (en) 2001-08-16
DK2196538T3 (en) 2015-01-05
TWI322184B (en) 2010-03-21
JP5165826B2 (ja) 2013-03-21
KR100884724B1 (ko) 2009-02-19
HK1056742A1 (zh) 2004-02-27
CA2398679C (en) 2015-11-17
FR13C0036I1 (fr) 2013-08-09
AU2009212900A1 (en) 2009-10-01
US6783965B1 (en) 2004-08-31
JP5341945B2 (ja) 2013-11-13
US7927852B2 (en) 2011-04-19
IL151065A0 (en) 2003-04-10
HUP0204544A3 (en) 2007-05-02
CZ304864B6 (cs) 2014-12-17
ES2524153T3 (es) 2014-12-04
EP1254237A2 (en) 2002-11-06
EP2305819B1 (en) 2014-11-12
MXPA02007545A (es) 2002-12-13
KR20080098686A (ko) 2008-11-11
HUP0204544A2 (en) 2003-05-28
WO2001059078A3 (en) 2002-03-07
EP2196538B1 (en) 2014-10-01
ATE463576T1 (de) 2010-04-15
RU2006107110A (ru) 2007-09-20
US8921064B2 (en) 2014-12-30
HU227127B1 (en) 2010-07-28
CA2398679A1 (en) 2001-08-16
BR0108386C1 (pt) 2011-12-20
PT2305819E (pt) 2015-06-01
EP2196538A1 (en) 2010-06-16
CY1117264T1 (el) 2017-04-26
CY1110142T1 (el) 2015-01-14
KR101054247B1 (ko) 2011-08-08
BR0108386B1 (pt) 2017-10-31
KR20020087934A (ko) 2002-11-23
RU2557318C2 (ru) 2015-07-20
AU2001249975B2 (en) 2006-06-08
DE60141742D1 (de) 2010-05-20
PT1254237E (pt) 2010-06-07
BE2013C045I2 (enFirst) 2020-06-24
JP2011188861A (ja) 2011-09-29
IL193365A0 (en) 2009-02-11
CY2013028I2 (el) 2015-11-04
CN101735991A (zh) 2010-06-16
KR20070092329A (ko) 2007-09-12
RU2281954C2 (ru) 2006-08-20
CN101735991B (zh) 2013-09-11
IL151065A (en) 2008-12-29
PL358539A1 (en) 2004-08-09
RU2557318C9 (ru) 2015-09-10
AU2009212900B2 (en) 2011-12-08
EP2305819A1 (en) 2011-04-06
JP2003521937A (ja) 2003-07-22
LU92237I2 (fr) 2013-09-03
CY2013028I1 (el) 2015-11-04
TW200914617A (en) 2009-04-01
RU2009104003A (ru) 2010-08-20
CN1423699A (zh) 2003-06-11
HK1144701A1 (en) 2011-03-04
AU4997501A (en) 2001-08-20
IL193365A (en) 2011-08-31
US20110287466A1 (en) 2011-11-24
DK2305819T3 (en) 2015-01-05
US20080057048A1 (en) 2008-03-06
CN100491532C (zh) 2009-05-27
RU2352354C2 (ru) 2009-04-20
BR0108386A (pt) 2002-10-29
CZ20022982A3 (cs) 2003-01-15

Similar Documents

Publication Publication Date Title
BRPI0108386B8 (pt) conjugado de uricase, composição farmacêutica e método para a purificação de uricase
Swann et al. The isolation and partial characterization of the major glycoprotein (LGP-I) from the articular lubricating fraction from bovine synovial fluid
BR0212999A (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
WO1992017188A1 (en) New non-anticoagulant heparin derivatives
RU2001103144A (ru) Конъюгаты peg-уратоксидазы и их использование
KR970706842A (ko) 아실화된 인슐린 동족체(Acylated Insulin Analogs)
EP1432802A2 (en) Pegylated and diglycosylated erythropoietin
JPS62246520A (ja) 白内障の予防及び逆転方法及び眼の組成物
Gupta et al. Subunit structure of porcine submaxillary mucin
RU2007145202A (ru) Использование tfpi для лечения тяжелых бактериальных инфекций
US20230338471A1 (en) Liquid formulations comprising mutant fgf-21 peptide pegylated conjugates
ATE549036T1 (de) Thymosin-alpha-1-peptid/polymer-konjugate
JP7689573B2 (ja) ポリエチレングリコール修飾尿酸オキシダーゼの製造方法
AU5071902A (en) A complex comprising OCIF and polysaccharide
US20060275279A1 (en) Methods for dissolving cystine stones and reducing cystine in urine
JP2002533473A (ja) 微生物起源のヒアルロン酸分解酵素を含有する薬学的配合物
CN102964442B (zh) 一种聚乙二醇同神经生长因子结合物的制备方法
Hoskins The ABO blood group antigens and their secretion by healthy and diseased gastric mucosa
US20150225710A1 (en) Coagulation Factor IX Conjugates
JPH02238879A (ja) Ｎ―ポリオシル―ポリペプチド
BR9916858A (pt) ((aminoiminometil)amino)alcanocarboxamidas e asaplicações das mesmas em terapia
WO1992017506A1 (en) MODULATION OF tPA ACTIVITY BY HEPARIN FRAGMENTS
Luvisetto Hyperthyroidism and mitochondrial uncoupling
EP1015483B1 (en) Malaria polypeptides
CA1066620A (en) Composition and method of using a protein mixture derived from liver

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: A FIM DE ATENDER AO SOLICITADO NA PETICAO DE ESCLARECIMENTO NO 018090054813-SP, DE 10/12/2009, DEVERA O TITULAR APRESENTAR ATRAVES DE FORMULARIO PROPRIO A SOLICITACAO DE TRANSFERENCIA PARCIAL DE TITULARIDADE.

B25A Requested transfer of rights approved

Owner name: MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) , DUKE UN

Free format text: TRANSFERIDO PARTE DOS DIREITOS DE: MOUNTAIN VIEW PHARMACEUTICALS, INC.

B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: A PETICAO DE NO 18120022985-SP, APRESENTADA EM 26/06/2012, EM VIRTUDE DO DISPOSTO NOS ARTS. 218 OU 219 DA LPI (LEI 9279 / 96) DE 14/05/1996, E CONSIDERADA COMO PETICAO NAO CONHECIDA, UMA VEZ QUE O SERVICO REQUERIDO REFERE-SE APENAS AO TITULAR DO DEPOSITO DE PATENTE OU DO PEDIDO DE PATENTE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 9/06 , A61K 47/48 , A61K 38/44

Ipc: A61K 38/44 (2006.01), C12N 9/06 (2006.01), C12N 9/

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: A PETICAO DE NO 18120022984, APRESENTADA EM 26/06/2012, EM VIRTUDE DO DISPOSTO NOS ARTS. 218 OU 219 DA LPI (LEI 9279 / 96) DE 14/05/1996, E CONSIDERADA COMO PETICAO NAO CONHECIDA POR AUSENCIA DE FUNDAMENTACAO LEGAL, UMA VEZ QUE O INPI NAO FAZ ANOTACOES DE ENDERECO DE INVENTOR.

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25B Requested transfer of rights rejected

Owner name: MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) , DUKE UN

B25H Request for change of headquarter rejected

Owner name: MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) , DUKE UN

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: A61K 38/44

Ipc: A61K 47/60 (2017.01), C12N 9/06 (2006.01), C12N 9/

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: A61K 38/44; C12N 9/06; C12N 9/96; A61K 47/48.

Ipc: A61K 47/60 (2017.01), C12N 9/06 (2006.01), C12N 9/

Ipc: A61K 47/60 (2017.01), C12N 9/06 (2006.01), C12N 9/

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: REFERENTE A 20A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/02/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 07/02/2021

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: